Androgen Function in the Pathophysiology and Treatment of Male Huntington's Disease Patients

被引:7
作者
Ransome, M. I. [1 ]
机构
[1] Univ Melbourne, Florey Neurosci Inst, Melbourne Brain Ctr, Parkville, Vic 3010, Australia
基金
英国医学研究理事会;
关键词
Huntington's disease; androgen; androgen receptor; hypogonadism; testosterone replacement therapy; gonadotrophic axis; GROWTH-FACTOR-I; RECEPTOR POLYMORPHISM; TESTOSTERONE THERAPY; DEPRESSIVE SYMPTOMS; DEPRIVATION THERAPY; PLASMA TESTOSTERONE; PROSTATE-CANCER; MOUSE MODEL; LATE-ONSET; BRAIN;
D O I
10.1111/j.1365-2826.2012.02347.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Low concentrations of circulating testosterone have been associated with dementia manifesting with advancing age and in neurodegenerative conditions. Huntingtons disease (HD) is a dominantly inherited neurodegenerative disease with an invariably fatal outcome. Severe motor symptoms, psychosis and dementia are symptomatic hallmarks of the progression of HD that result from the dysfunction and death of neocortical and basal ganglia neurones. Treatments are directed toward manifest symptoms, although they are largely ineffectual in slowing or preventing disease progression. Emerging data have identified hypothamic pathologies in HD that result in endocrine disturbances. Clinically defined primary or secondary hypogonadism elicit low circulating testosterone concentrations and have been linked to the development of Alzheimers disease in men. Examining similar neuroendocrine dysfunction in HD including the nature of manifest hypogonadism in male patients could allow an elucidation of the complex pathophysiology of HD and provide an impetus for hitherto untested testosterone replacement therapy.
引用
收藏
页码:1275 / 1283
页数:9
相关论文
共 50 条
  • [21] Huntington's Disease: Function and Dysfunction of Huntingtin in Axonal Transport
    Saudou, Frederic
    Humbert, Sandrine
    INTRACELLULAR TRAFFIC AND NEURODEGENERATIVE DISORDERS, 2009, : 115 - +
  • [22] Visual function in Huntington's disease patients and presymptomatic gene carriers
    O'Donnell, BF
    Wilt, MA
    Hake, AM
    Stout, JC
    Kirkwood, SC
    Foroud, T
    MOVEMENT DISORDERS, 2003, 18 (09) : 1027 - 1034
  • [23] DNA Methylation in Huntington's Disease
    Zsindely, Nora
    Siagi, Fruzsina
    Bodai, Laszlo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [24] Targeting Histone Deacetylases for the Treatment of Huntington's Disease
    Gray, Steven G.
    CNS NEUROSCIENCE & THERAPEUTICS, 2010, 16 (06) : 348 - 361
  • [25] The Effect of Severe Androgen Deficiency on Physical Function in Male Patients With Cancer
    Gagnon, Bruno
    Murphy, Jessica
    Jelowicki, Marta
    Morris, David V.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2013, 45 (05) : 892 - 900
  • [26] Treatment options in Huntington's disease
    Lopez-Sendon Moreno, Jose Luis
    Garcia de Yebenes, Justo
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (11): : 901 - 914
  • [27] Treatment of Huntington's disease with galantamine
    Petrikis, P
    Andreou, C
    Piachas, A
    Bozikas, VP
    Karavatos, A
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (01) : 49 - 50
  • [28] Deutetrabenazine in the treatment of Huntington's disease
    Richard, Alby
    Frank, Samuel
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2019, 9 (01) : 31 - 36
  • [29] Fluoxetine in the treatment of Huntington's disease
    De Marchi, N
    Daniele, F
    Ragone, MA
    PSYCHOPHARMACOLOGY, 2001, 153 (02) : 264 - 266
  • [30] Therapeutic strategies for Huntington's disease
    Estevez-Fraga, Carlos
    Flower, Michael D.
    Tabrizi, Sarah J.
    CURRENT OPINION IN NEUROLOGY, 2020, 33 (04) : 508 - 518